Latest Headlines

Latest Headlines

PureTech banks $171M in a London IPO to fund its biotech bets

Biotech startup engine PureTech pulled off a $171 million IPO on the London Stock Exchange, crossing the Atlantic to raise cash for its hybrid approach to venture investing.

Lilly and Teva tout new migraine data amid a crowded race

Eli Lilly and Teva, racing with a pack of drugmakers with a new approach to treating migraines, said their respective injected therapies succeeded in midstage trials, setting the stage for pivotal studies.

Antibiotics biotech Nabriva shoots for a $92M IPO

Austrian drug developer Nabriva Therapeutics is plotting to make its way to Wall Street in a $92 million IPO, raising cash to support its pipeline of treatments for infectious diseases.

Video: Blazing a short path to an accelerated approval in oncology

At the 2015 BIO conference in Philadelphia, FierceBiotech Editor-in-Chief John Carroll moderates a discussion on the future of cancer R&D, featuring leaders from AstraZeneca, Juno Therapeutics, Merck, Johnson & Johnson and GlaxoSmithKline.

Medtronic buys into Arsenal, gets option to purchase the post-surgical foam startup subsidiary

Medtronic has invested in a subsidiary of Arsenal Medical, a startup focused on developing a polymer-based foam to control intra-abdominal bleeding. The device giant gains an option to acquire the subsidiary, Arsenal AAA, upon the achievement of undisclosed milestones. Medtronic also didn't reveal how much it invested in the deal.

UPDATED: Cynvenio Biosystems ropes in $25M for liquid biopsy technology

California diagnostics outfit Cynvenio Biosystems reeled in $25.5 million in Series B financing to support development of its liquid biopsy technology, critical funding as the company looks to generate growth at home and abroad.

Quintiles beefs up its risk-based monitoring tech

Quintiles has rewired its risk-based monitoring service to include analytics technology the CRO says can better predict pressure points in clinical trials, touting its new offering as the first of its kind.

Merck KGaA hustling a promising anti-malaria drug into human studies

Scientists in Scotland have been grabbing headlines with news that their preclinical research into an experimental single-dose antimalaria compound has shown real promise, spurring Merck KGaA to pick up the development and commercialization rights.

NIH finds sand fly saliva may be the key to leishmaniasis vaccine

Researchers at the National Institutes of Health reported that a leishmaniasis vaccine based on sand fly saliva has worked well in monkeys. 

Connecticut company wins grant to deploy stem cells for organ regeneration

MultiClonal Therapeutics has been awarded a $750,000 grant to develop personalized therapies for chronic lung diseases like COPD.